INTRODUCTION: P-selectin is a cell adhesion molecule shown to play a role in venous thromboembolism. We evaluated whether higher P-selectin is associated with chronic venous insufficiency (CVI). MATERIALS AND METHODS: In a cohort of 2408 participants, the San Diego Population Study, peripheral venous disease was established by symptoms, clinical examination, and ultrasound. We measured P-selectin in a subsample of 352 CVI cases frequency matched to controls. Cases included four hierarchical groups of increasing severity of CVI. RESULTS: The association of P-selectin with CVI considering all cases was weak, with an age, race and sex-adjusted odds ratio (OR) of 1.3 (95% CI 1.0-2.2) for values in the 3rd versus 1st tertile. The OR for cases in the two most severe groups was 2.3 (95% CI 1.2-4.2). Addition of body mass index to the model reduced this OR to 1.9 (95% CI 1.0-3.6). CONCLUSIONS: Higher circulating P-selectin was associated with more severe CVI, but not CVI overall. Results support that platelet and endothelial cell activation may be involved in the pathogenesis of CVI.
INTRODUCTION:P-selectin is a cell adhesion molecule shown to play a role in venous thromboembolism. We evaluated whether higher P-selectin is associated with chronic venous insufficiency (CVI). MATERIALS AND METHODS: In a cohort of 2408 participants, the San Diego Population Study, peripheral venous disease was established by symptoms, clinical examination, and ultrasound. We measured P-selectin in a subsample of 352 CVI cases frequency matched to controls. Cases included four hierarchical groups of increasing severity of CVI. RESULTS: The association of P-selectin with CVI considering all cases was weak, with an age, race and sex-adjusted odds ratio (OR) of 1.3 (95% CI 1.0-2.2) for values in the 3rd versus 1st tertile. The OR for cases in the two most severe groups was 2.3 (95% CI 1.2-4.2). Addition of body mass index to the model reduced this OR to 1.9 (95% CI 1.0-3.6). CONCLUSIONS: Higher circulating P-selectin was associated with more severe CVI, but not CVI overall. Results support that platelet and endothelial cell activation may be involved in the pathogenesis of CVI.
Authors: H G Beebe; J J Bergan; D Bergqvist; B Eklof; I Eriksson; M P Goldman; L J Greenfield; R W Hobson; C Juhan; R L Kistner; N Labropoulos; G M Malouf; J O Menzoian; G L Moneta; K A Myers; P Neglen; A N Nicolaides; T F O'Donnell; H Partsch; M Perrin; J M Porter; S Raju; N M Rich; G Richardson; D S Sumner Journal: Eur J Vasc Endovasc Surg Date: 1996-11 Impact factor: 7.069
Authors: Bo Eklöf; Robert B Rutherford; John J Bergan; Patrick H Carpentier; Peter Gloviczki; Robert L Kistner; Mark H Meissner; Gregory L Moneta; Kenneth Myers; Frank T Padberg; Michel Perrin; C Vaughan Ruckley; Philip Coleridge Smith; Thomas W Wakefield Journal: J Vasc Surg Date: 2004-12 Impact factor: 4.268
Authors: P Prandoni; A W Lensing; A Cogo; S Cuppini; S Villalta; M Carta; A M Cattelan; P Polistena; E Bernardi; M H Prins Journal: Ann Intern Med Date: 1996-07-01 Impact factor: 25.391
Authors: Michael H Criqui; Maritess Jamosmos; Arnost Fronek; Julie O Denenberg; Robert D Langer; John Bergan; Beatrice A Golomb Journal: Am J Epidemiol Date: 2003-09-01 Impact factor: 4.897
Authors: Jan K Nowak; Irena Wojsyk-Banaszak; Edyta Mądry; Andrzej Wykrętowicz; Patrycja Krzyżanowska; Sławomira Drzymała-Czyż; Agata Nowicka; Andrzej Pogorzelski; Ewa Sapiejka; Wojciech Skorupa; Mariusz Szczepanik; Aleksandra Lisowska; Jaroslaw Walkowiak Journal: Lung Date: 2017-06-23 Impact factor: 2.584